The NHLBI has put an early stop to the large Cardiovascular Inflammation Reduction (CIRT) Trial. The NHLBI action was based on a recommendation from the trial’s Data and Safety Monitoring Board. The action was not based on any substantive safety concerns. “Sometime in late March or early April the NHLBI informed me that there were no substantive…
Imaging Studies Offer New Insights Into Inflammation In CV Disease
October 19, 2017 by 2 Comments
–Preliminary evidence that colchicine may reduce coronary plaque. Interest in inflammation has risen considerably in the cardiology community as a result of the recent CANTOS trial. The large 10,000 patient trial validated the role of inflammation by demonstrating the efficacy of canakinumab— a monoclonal antibody that targets interleukin-1β— in reducing cardiovascular events in people with…
NHLBI Announces 7000 Patient Trial Testing Inflammation Hypothesis
August 22, 2012 by 2 Comments
The National Heart, Lung, and Blood Institute (NHLBI) has announced the launch of a large clinical trial testing the inflammation hypothesis. Paul Ridker is the principal investigator of the trial, which will be known as the Cardiovascular Inflammation Reduction Trial (CIRT). CIRT will enroll 7,000 patients who are stable following a heart attack but are at high…
Recent Comments